Company Insights

IPSC supplier relationships

Explore interactive graphBrowse insights index
IPSC supplier relationship map

Century Therapeutics (IPSC): supplier relationships that drive clinical throughput and capital cadence

Century Therapeutics develops off-the-shelf iPSC-derived cell therapies and monetizes through collaborative manufacturing and licensing arrangements, milestone/royalty terms tied to downstream commercialization, and periodic equity financings to fund clinical development. The company's value proposition rests on translating proprietary iPSC lines into scalable therapeutic products while outsourcing critical manufacturing and using partner-backed financings to preserve runway. Explore strategic supplier exposure and financing counterparties at https://nullexposure.com/.

How Century structures supply and commercialization risk

Century operates a hybrid model: R&D and IP ownership internally, production and scale largely outsourced to specialized third parties. That posture produces predictable operating levers — licensing fees, milestones and royalties on future product sales — while concentrating execution risk with a small number of manufacturing partners.

  • Contracting posture is long-term and exclusivity-driven for key clinical material: Century's manufacturing agreement with FUJIFILM Cellular Dynamics, Inc. (FCDI) includes exclusivity provisions that last through the fifth anniversary of the agreement and extend options for exclusivity on follow-on products, which creates a single-supplier dependency for certain clinical-grade products (Century’s 2024 Form 10‑K).
  • The company relies on third‑party CMOs and service providers for cGMP manufacture and testing, which makes counterparty performance operationally critical and legally sensitive; the 10‑K discloses technology transfers and process development explicitly performed by FCDI.
  • Spending history on some license and milestone obligations is relatively small to date, consistent with early-stage biotechs: Century disclosed payments in the low‑thousands for certain FCDI-related items and capped milestone schedules under a sublicense with iCELL, reflecting structured, milestone-driven outflows rather than large fixed manufacturing spend in the historical record.

These signals combine into a clear investment architecture: high product concentration and operational criticality on a limited set of suppliers, paired with milestone/royalty monetization and episodic capital raises. For a deeper look at supplier counterparty exposures, visit https://nullexposure.com/.

Supplier and financing counterparties that matter right now

FUJIFILM Cellular Dynamics, Inc.
Century has a multi‑faceted relationship with FUJIFILM Cellular Dynamics: FCDI is both a licensor of iPSC-related patents/know‑how under a non‑exclusive license and a contract manufacturer and service provider under a March 2021 Manufacturing Agreement that covers technology transfer, process development, analytical testing and cGMP manufacture for clinical supply; the 2024 Form 10‑K documents upfront payments, milestone/royalty obligations and exclusivity provisions tied to clinical-grade CNTY‑101 (Century’s 2024 10‑K; GlobeNewswire press release, Mar 2025).
Source: Century Therapeutics’ 2024 Form 10‑K and the company’s March 19, 2025 press release on full‑year results.

Leerink Partners
Leerink acted as a placement agent on Century’s oversubscribed private placement, reflecting active equity capital markets support for the company’s near‑term financing needs (news coverage of the March 2026 private placement).
Source: InvestingNews and Yahoo Finance coverage of Century’s March 2026 private placement.

TD Cowen
TD Cowen participated as a placement agent alongside Leerink and Mizuho on the same equity financing, demonstrating a syndicate approach to securing growth capital (news coverage, March 2026).
Source: Yahoo Finance and InvestingNews reporting on the March 2026 private placement.

Mizuho
Mizuho served as a placement agent on Century’s March 2026 private placement, completing the syndicate that executed the oversubscribed $135 million raise to support lead programs (public news releases, March 2026).
Source: Yahoo Finance and InvestingNews reporting (March 2026).

Why each relationship matters for valuations and downside

  • FCDI is the single most consequential commercial supplier: the exclusivity and manufacturing role mean any disruption in FCDI’s performance would directly affect trial supply and timelines, which are the primary drivers of milestone receipts and eventual royalties. The 10‑K discloses explicit exclusivity to the fifth anniversary and options for additional products, underscoring concentrated counterparty risk.
  • Licensing economics are structured to conserve cash up‑front and capture upside on commercialization: royalties in the low single digits and milestone payment schedules shift near‑term cash flow risk to development outcomes, limiting current spend but creating long‑term revenue upside if programs succeed (10‑K licensing terms).
  • Capital markets relationships (Leerink, TD Cowen, Mizuho) reduce financing execution risk: the participation of multiple placement agents in the March 2026 private placement that raised $135 million improves access to follow‑on capital and reduces the probability of a dilutive distressed raise in the near term, but recurring capital dependence remains a fundamental valuation lever (news coverage, March 2026).

For investors evaluating counterparty exposure, operational concentration on a single manufacturer coupled with milestone‑heavy licensing points to binary program risk and lumpy revenue realization. If you want structured intelligence on supplier concentration and how it maps to trial timelines, start here: https://nullexposure.com/.

Practical monitoring checklist for operators and investors

  • Track FCDI operational milestones and the fifth‑anniversary exclusivity window to assess supply flexibility.
  • Monitor milestone realization events that trigger royalties or partner payments; these events materially alter cash flow visibility.
  • Watch investor syndicate behavior (bookrunners/placement agents) as a proxy for financing optionality and cost of capital.

Closing view and action points

Century’s commercial upside is concentrated: execution of clinical manufacturing with FUJIFILM Cellular Dynamics and successful capital raises via knowledgeable placement agents are the two levers that will determine near‑term value realization. Operational continuity at FCDI and the timing of milestone triggers are the closest thing to a pulse check on enterprise risk.

If you are assessing counterparty risk or building a supplier‑level view for IPSC, review the detailed supplier and financing profiles at https://nullexposure.com/ and subscribe for updates on material contract amendments and financing activity.